Stocks TradingCharts.com

stocks prices, charts & quotes

Free Stock Prices, Charts & Stock Price Quotes

Search
Symbol Search Browse Symbols My Charts Menu
QUICK QUOTE
QUICK CHART
F.A.Questions Suggestion Box Advertising Info Commodity Charts Forex Markets

Stocks & Financial News

Breaking financial news 24/7 courtesy of TradingCharts.com Inc. / TFC Commodity Charts

Sabra Health Care REIT, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call

TUSTIN, Calif., April 24, 2024 (BUSINESS WIRE) --
Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced today that it will issue its 2024 first quarter earnings release on May 8, 2024, after the close of trading.

A conference call with a simultaneous webcast to discuss the 2024 first quarter results will be held on Thursday, May 9 at 10:00 a.m. Pacific Time. The dial-in number for U.S. participants is 888-880-4448. For participants outside the U.S., the dial-in number is 646-960-0572. The conference ID number is 1382596.

The webcast URL is https://events.q4inc.com/attendee/588244325. A digital replay of the call will be available on our website at www.sabrahealth.com.

About Sabra

Sabra Health Care REIT, Inc., a Maryland corporation, operates as a self-administered, self-managed real estate investment trust (a "REIT") that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240424255988/en/

SOURCE: Sabra Health Care REIT, Inc.

<img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&sty=20240424255988r1&sid=cmtx6&distro=nx&lang=en" style="width:0;height:0" />

Investor & Media Inquiries: 1-888-393-8248 or investorinquiries@sabrahealth.com
comtex tracking

COMTEX_451357399/1006/2024-04-24T16:05:02

Do not sell my personal information

Copyright © 2024. All market data is provided by Barchart Solutions. Information is provided "as is" and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.